Every year, thousands of children with leukaemia are treated with a drug that traces back to a pink flower growing wild on the dry coasts of southern Madagascar. The flower is the Madagascar periwinkle. The drugs it gave the world, vincristine and vinblastine, are still on the World Health Organization's list of essential medicines, still saving lives more than sixty years after they were discovered. Madagascar, where the plant comes from and where people had used it in traditional medicine for generations, received almost none of the money. That gap, between who held the knowledge and who banked the profit, is the founding story of a fight that is still going on today.
A weed in Madagascar, a remedy in the folk pharmacopoeia
The Madagascar periwinkle, Catharanthus roseus, is native and endemic to Madagascar, though it now grows in gardens and roadsides across the tropics. In Madagascar it was a familiar medicinal plant, and as it travelled the world it picked up a reputation in folk medicine as a treatment for diabetes. Healers in several countries brewed its leaves into teas. That reputation, half a world away from the island, is what brought the plant to the attention of science. It is a pattern worth remembering: the lead did not come from a laboratory. It came from traditional use, passed along until it reached people with the tools to test it.
The diabetes drug that wasn't
In 1952, a Canadian physician named Clark Noble received an envelope from a patient who had visited Jamaica. Inside were twenty-five periwinkle leaves and a description of the tea Jamaicans made from them for diabetes. Noble sent the leaves to his brother, Robert Laing Noble, a researcher at the University of Western Ontario. The extracts did almost nothing to blood sugar. What they did instead was alarming: the test animals' white blood cell counts collapsed and their bone marrow shut down. A weaker team might have filed the plant away as a poison and moved on. The Nobles and chemist Charles Thomas Beer followed the toxicity instead, reasoning that a substance which so powerfully attacked white blood cells might attack cancerous ones. By 1958 they had isolated the responsible compound, vinblastine. The pharmaceutical company Eli Lilly, screening the same plant independently, isolated a sister compound, vincristine. The full story of the chance discovery is told in this account of the flower behind vincristine.
Two drugs that changed childhood cancer
The timing mattered. In the 1950s, a child diagnosed with acute lymphoblastic leukaemia, the most common childhood cancer, had almost no chance of survival. Vincristine became a backbone of the combination chemotherapy regimens that changed that, and it remains central to treating the disease today, alongside roles in lymphomas and other cancers. Vinblastine found its place against Hodgkin lymphoma and several solid tumours. Both drugs are still manufactured from a plant that produces the active compounds in vanishingly small amounts, which is why periwinkle cultivation and wild collection continued for decades, including around Fort Dauphin and Ambovombe in Madagascar itself, where collectors gathered leaves and roots for export as raw material. The plant's chemistry and history are summarised in the Madagascar periwinkle reference entry. Africa Rebirth has told this kind of story before, in our roundup of African medical innovations the West claims to have invented. The periwinkle is the sharpest case of all, because the value was so enormous and the return so small.
The money that never came home
Vinblastine and vincristine generated very large revenues over decades of clinical use. Madagascar's share was effectively nothing beyond the low prices paid to the collectors who gathered the plant. No royalty flowed back to the island, and no share reached the traditional knowledge holders whose use of the plant had pointed researchers toward it. When a Western company later took out a patent, in 2001, on periwinkle-derived drugs, the contrast hardened into a word that has followed the case ever since: biopiracy. Defenders of the discovery point out, fairly, that the science was real, difficult and expensive, and that the folk use was for diabetes, not cancer. Both things are true. The drugs exist because Canadian and American researchers did brilliant work. They also exist because a Madagascan plant, carried around the world by people who used it as medicine, landed on the right laboratory bench.
The lesson the world is still learning
The periwinkle case became one of the exhibits that pushed the world toward rules. The Nagoya Protocol, the international agreement on access and benefit-sharing that came into force in 2014, exists so that the next periwinkle is negotiated rather than simply taken: researchers get access to genetic resources and traditional knowledge, and the countries and communities they come from get a defined share of what results. Some African industries have since won exactly that kind of deal. The harder question the flower leaves behind is about capacity. Benefit-sharing on someone else's drug is a royalty. Screening your own flora, in your own laboratories, is an industry. Madagascar's periwinkle still grows wild on the coast where it started. What Africa knew was never the problem. Who got to build on it was.